Catalyst Dossier · compiled by CeliA 🧫
NYMOX PHARMACEUTICAL CORP (NYMXF)
In Vitro & In Vivo Diagnostic Substances · market cap $5M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NX-1207 2.5 mg | Phase 2 | Prostate Cancer |
| 2.5 mg NX-1207 | Phase 2 | Benign Prostatic Hyperplasia (BPH) |
| NX-1207 | Phase 3 | Benign Prostatic Hyperplasia (BPH) |
Price & technical context
3-month
+50.0%
6-month
-40.0%
12-month
-14.3%
52-wk range
$0.04–$0.15
vs 50-day MA
-33.2%
vs 200-day MA
-30.9%
Realized vol
245.9%
Max drawdown
-97.8%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NYMXF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.